DNAPrint CEO Richard Gabriel's Interview With Wall Street Reporter Magazine Available Via Web Cast

DNAPrint CEO Richard Gabriel's Interview With Wall Street
Reporter Magazine Available Via Web Cast 


SARASOTA, Fla., June 22  /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC:DNAP) (BULLETIN BOARD: DNAP)  today announced that President and Chief
Executive Officer Richard Gabriel is the subject of an interview and web cast
with the Wall Street Reporter magazine.

During the interview, which can be accessed free at
http://www.wallstreetreporter.com/ , Mr. Gabriel discussed the future of
pharmacogenomics and DNAPrint's recent licensing agreement with the Harvard
Medical School's Beth Israel Deaconess Medical Center (BIDC) to clinically
develop and commercially implement a new, super-potent form of erythropoietin
(EPO), an anemia treatment drug.

"We believe that the recent FDA pronouncements about pharmacogenomics and the
importance of understanding genetic ancestry of patients in combination with
drug treatments is the wave of the future," Mr. Gabriel stated. "In fact, we
see all drugs, or let's say a good majority of those drugs 10, 15, 20 years
from now, and this is just my personal opinion, will have what we would call a
diagnostic test tied directly to the administration of the drug so everyone
knows that it is being personalized medically."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of
genomics-based products and services focused on drug development,
pharmacogenomic diagnostic tests, forensics technology and consumer genetic
tests. The Company's first theranostic product (drug/test combination) is PT-
401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia
in renal dialysis patients (end stage renal disease). Currently in pre-
clinical development, PT-401 will be targeted to patients with a genetic
profile indicating their propensity to have the best clinical response.

Forward-Looking Statements

All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected,
including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory approvals,
competition, intellectual property of others, and patent protection and
litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in DNAPrint's expectations
with regard thereto or any change in events, conditions, or circumstances on
which any such statements are based.

   Company Contact:
   Richard Gabriel
   President and CEO
   941-366-3400
        -or-
   Ron Stabiner
   The Wall Street Group, Inc.
   212-888-4848


http://www.wallstreetreporter.com/DATASOURCE: DNAPrint genomics, Inc.



CONTACT:  Richard Gabriel, President and CEO of DNAPrint genomics,

[phone]; or Ron Stabiner of The Wall Street Group, Inc.,

[phone], for DNAPrint genomics



Web site:  http://www.dnaprint.com/ 

Copyright